SCHEMBL27140667

SCHEMBL27140667

CC(C)(C)OC(=O)N1CCN(CCCOC2CCN(C(=O)c3ccc(Cl)c(N4CCC(=O)NC4=O)c3)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 4/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CCR5 P51681 1/20 0.39
▸ HRH2 P25021 2/20 0.38
▸ HRH1 P35367 2/20 0.38
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ PDK3 Q15120 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ HRH3 Q9Y5N1 2/20 0.38
▸ DDB1 Q16531 3/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ EPHX2 P34913 3/20 0.37
▸ DRD2 P14416 1/20 0.36
▸ AURKA O14965 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ TTK P33981 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27137466 0.91 GPR119 (0.41) MEN1KMT2APDK1PDK2PDK3
SCHEMBL31677220 0.91 MEN1 (0.41) CRBNMEN1KMT2ACCR5PDK1
SCHEMBL31024371 0.89 GPR119 (0.43) CRBNMEN1KMT2ACCR5PDK1
SCHEMBL27123897 0.89 GPR119 (0.43) CRBNMEN1KMT2ACCR5PDK1
SCHEMBL27139528 0.89 HRH3 (0.39) MEN1KMT2AHRH3DRD2
SCHEMBL27137616 0.88 CRBN (0.39) CRBNMEN1KMT2ACCR5PDK1
SCHEMBL31024352 0.87 GPR119 (0.45) CRBNMEN1KMT2APDK1PDK2
SCHEMBL27137321 0.87 HRH3 (0.40) HRH2HRH1HRH3DRD2
SCHEMBL23121362 0.86 KMT2A (0.44) CRBNMEN1KMT2APDK1PDK2
SCHEMBL31161308 0.86 CNR1 (0.43) CRBNMEN1KMT2APDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 — — US disclosed
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 — — US disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SOS1, RAC1, RSU1 CRBN 802/4885MEN1 805/4885KMT2A 4200/4885
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RAC1, SOS1, RSU1 CRBN 606/4885MEN1 920/4885KMT2A 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback